SCHOTT Pharma Reports Steady Q3 2025 Results

SCHOTT Pharma AG & Co. KGaA announced solid third-quarter results for 2025, highlighting a 1% increase in revenue year-over-year to EUR 256 million, or 3% at constant currencies. The company achieved an EBITDA margin of 32.4% and anticipates a full-year margin around 28.0%.

High-value solutions (HVS) played a pivotal role, contributing to 60% of Q3 revenues. The Drug Containment Solutions segment saw a 4% revenue increase to EUR 142 million. Despite a 2% revenue decline in the Drug Delivery Systems segment, strong glass syringe performance helped maintain stability.

SCHOTT Pharma also focused on innovation, introducing new cartridge solutions to support self-administration of medications. The company aims for a 6.0% organic revenue growth for FY 2025, driven by demand for advanced drug delivery solutions.